Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 14Neoplasm Metastasis 7Recurrence 3Neoplasms 2Melanoma 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pre-menopausal Breast Cancer 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Meningioma 1Kidney Neoplasms 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ductal, Breast 1Advanced or Metastatic ER+ Breast Cancer 1Advanced and Selected Solid Tumors 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1Advanced Solid Tumor 1Acrocephalosyndactylia 13rd Line GIST 1

Interventions

Dexamethasone 129Lenalidomide 70Cyclophosphamide 70Bortezomib 69Calcium Dobesilate 50fludarabine 44pomalidomide 40daratumumab 37carfilzomib 33fludarabine phosphate 31Melphalan 25dexamethasone acetate 20dexamethasone 21-phosphate 20auricularum 18Filgrastim 18Whole-Body Irradiation 14Biopsy 13isatuximab 12Vorinostat 12Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Granulocyte Colony-Stimulating Factor 12Specimen Handling 11Sirolimus 11ixazomib 10belantamab mafodotin 10Panobinostat 10Mycophenolic Acid 10Cyclosporine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Multiple Myeloma × Alpelisib × Clear all
NCT02144038 2020-12-17

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Novartis

Phase 1 Completed
20 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡